Dasatinib in solid tumors

Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up

(2009) H. Kantarjian et al.   BLOOD

Latent Bone Metastasis in Breast Cancer Tied to Src-Dependent Survival Signals

(2009) Xiang H.-F. Zhang et al.   CANCER CELL

Phase II Study of Dasatinib in Patients with Metastatic Castration-Resistant Prostate Cancer

(2009) E. Y. Yu et al.   CLINICAL CANCER RESEARCH

Phase I Dose-Escalation and Pharmacokinetic Study of Dasatinib in Patients with Advanced Solid Tumors

(2009) G. D. Demetri et al.   CLINICAL CANCER RESEARCH

Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy

(2009) S Mustjoki et al.   LEUKEMIA

Effects of Src kinase inhibition induced by dasatinib in non-small cell lung cancer cell lines treated with cisplatin

(2009) P. Ceppi et al.   MOLECULAR CANCER THERAPEUTICS

Target profiling of small molecules by chemical proteomics

(2009) Uwe Rix et al.   Nature Chemical Biology

Src kinases as therapeutic targets for cancer

(2009) Lori C. Kim et al.   Nature Reviews Clinical Oncology

Src as a potential therapeutic target in non-small-cell lung cancer

(2008) G. Giaccone et al.   ANNALS OF ONCOLOGY

Targeting Src in breast cancer

(2008) R. S. Finn   ANNALS OF ONCOLOGY

Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCEL™), a multi-targeted kinase inhibitor

(2008) Feng (Roger) Luo et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Sprycel for Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Resistant to or Intolerant of Imatinib Mesylate

(2008) M. Brave et al.   CLINICAL CANCER RESEARCH

Targeting Src signaling in metastatic bone disease

(2008) John Araujo et al.   INTERNATIONAL JOURNAL OF CANCER

Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells

(2008) L L Remsing Rix et al.   LEUKEMIA

A quantitative analysis of kinase inhibitor selectivity

(2008) Mazen W Karaman et al.   NATURE BIOTECHNOLOGY